Dual role of exosomes in pancreatic cancer: Underlying mechanisms and research advances (Review).
OpenAlex 토픽 ·
Extracellular vesicles in disease
Caveolin-1 and cellular processes
Cancer, Lipids, and Metabolism
Pancreatic cancer is one of the most common malignant tumors.
APA
Zhao Guo, Qingfeng Liu (2026). Dual role of exosomes in pancreatic cancer: Underlying mechanisms and research advances (Review).. Oncology letters, 31(5), 192. https://doi.org/10.3892/ol.2026.15547
MLA
Zhao Guo, et al.. "Dual role of exosomes in pancreatic cancer: Underlying mechanisms and research advances (Review).." Oncology letters, vol. 31, no. 5, 2026, pp. 192.
PMID
41947900
Abstract
Pancreatic cancer is one of the most common malignant tumors. Due to late diagnosis and a lack of effective treatments, pancreatic cancer has a poor prognosis and a high mortality rate. Further understanding of the mechanisms underlying the development and progression of pancreatic cancer is key to developing rational diagnostic and therapeutic strategies. Exosomes are small vesicles secreted by most cells, carrying a rich cargo of lipids, proteins and nucleic acids. Exosomes serve various roles in intercellular communication, biological processes and signal transduction. Notably, exosomes exhibit a dual role in pancreatic cancer: Exosomes can directly promote tumor cell proliferation, growth and metastasis, modulate the complex immunosuppressive microenvironment and contribute to chemoresistance; by contrast, exosomes can serve as biomarkers for diagnosis and drug delivery vehicles. The present study systematically reviewed the mechanisms through which exosomes exert their dual functions via their specific biomolecular cargo in pancreatic cancer, as well as their potential applications in diagnosis and treatment, thereby laying a research foundation for exosomes to potentially serve a more active role in pancreatic cancer in the future.
같은 제1저자의 인용 많은 논문 (5)
- Discovery of novel and potent 2-aminopyrazine-based HPK1 inhibitors enhancing T-cell immunity against cancer.
- RASGEF1B suppresses hepatocellular carcinoma through the ALDH7A1/Betaine/SNAI1 metabolic‒epigenetic axis.
- Mitochondria Pathway Signature Predicts Prognosis and Therapeutic Response and Identifies REXO2 as a Crucial Regulator in Breast Cancer.
- The microbial metabolite I3A inhibits ferroptosis and the effectiveness of redox-based cancer therapy.
- Correction: Guo et al. Shikonin as a WT1 Inhibitor Promotes Promyeloid Leukemia Cell Differentiation. 2022, , 8264.